SEC Filing Summary: Sarepta Therapeutics, Inc. (Form 13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Sarepta Therapeutics, Inc., acting as an Institutional Investment Manager. The report covers the quarter ended June 30, 2026, and was signed on August 13, 2026, by Ryan Wong, Executive Vice President and Chief Financial Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. Form 13F filings are designed to disclose equity holdings managed by institutional investors, not the operating financial results of the reporting entity itself. The report indicates a total value of holdings reported as $0.
Material Changes
The filing lists a total of 1 entry in the Information Table but reports a total value of $0. No comparative data or material changes in holdings value are provided in the text.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of portfolio holdings rather than an operational report.
Investor Verification Checklist
- Verify the nature of the filing: This is a 13F-HR (Holdings Report), not a 10-Q or 10-K containing financial performance data.
- Confirm the reported holdings value: The summary page explicitly states a "Value Total" of $0.
- Check for missing schedules: The provided text includes the cover page and summary but does not contain the detailed Schedule 13F listing the specific securities held.
- Validate the reporting entity: Ensure Sarepta Therapeutics, Inc. is correctly identified as the "Institutional Investment Manager" in this specific context, as it is primarily known as a biopharmaceutical company.